Oasmia Pharmaceutical

About:

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology.

Website: http://www.oasmia.com

Twitter/X: Oasmia

Top Investors: Yorkville Advisors

Description:

Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents.

Total Funding Amount:

$37M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Uppsala, Uppsala Lan, Sweden

Founded Date:

1990-01-01

Contact Email:

info(AT)oasmia.com

Founders:

Julian Aleksov

Number of Employees:

51-100

Last Funding Date:

2019-03-05

IPO Status:

Public

Industries:

© 2025 bioDAO.ai